IRWD_OUT_1 [2025-04-29 09:14:53 -0400] 4689 Bytes | 1333 tokens | Cum: 1333 tkns (16.66% of 8k)
==========================================================================

Captain's log, 9:14 AM on Tue Apr 29, 2025. Target in sight: Ironwood Pharmaceuticals (IRWD), moving from $0.8885 to $0.9700. Risk: acceptable. Opportunity: unknown. We proceed to analysis.

--- COMPANY PROFILE ---
Company: Ironwood Pharmaceuticals (IRWD)
IPO: IPO date unknown
Shares Outstanding: 160,030,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here’s a list of headlines for Ironwood Pharmaceuticals:

Apr-28-25 10:25AM - The 1-Minute Market Report April 27, 2025
Apr-25-25 07:05AM - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Apr-22-25 04:05PM - Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Apr-16-25 01:07PM - Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
Apr-15-25 09:18AM - Ironwood Shares Tank on Regulatory Update for Apraglutide
Apr-15-25 09:18AM 07:12AM - Ironwoods shares sink as FDA demands new trial for lead drug
Apr-14-25 07:00AM - Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Apr-13-25 10:44AM - The 1-Minute Market Report April 13, 2025
Apr-10-25 10:49AM - Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
Apr-10-25 10:49AM 09:25AM - Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday?
Apr-01-25 10:28AM - Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Mar-31-25 08:05AM - The 1-Minute Market Report March 30, 2025
Mar-27-25 04:05PM - Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Mar-25-25 11:08AM - Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
Mar-02-25 12:24PM - Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?
Feb-28-25 02:14AM - Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ...
Feb-27-25 11:20PM - Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call
Feb-27-25 11:20PM 08:15AM - Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
Feb-27-25 11:20PM 07:20AM - Ironwood: Q4 Earnings Snapshot
Feb-27-25 11:20PM 07:00AM - Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Feb-26-25 08:13AM - Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For
Feb-20-25 04:00PM - Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-14T18:19:35Z - Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
B2 - 2024-12-06T12:00:00Z - Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
B3 - 2024-07-05T10:31:01Z - New Strong Sell Stocks for July 5th - Zacks Investment Research
B4 - 2024-05-10T15:16:00Z - Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
B5 - 2024-05-02T14:01:14Z - Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
B6 - 2024-03-25T13:57:00Z - OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Ironwood Pharmaceuticals (IRWD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

IRWD_OUT_3 [2025-04-29 09:14:53 -0400] 748 Bytes | 194 tokens | Cum: 1529 tkns (19.11% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/25/04/44798343/ironwood-pharmaceuticals-stock-plunges-fda-wants-another-trial-for-gastrointestinal-drugIronwood Pharmaceuticals' stock plunged after the FDA requested a confirmatory Phase 3 trial for its gastrointestinal drug apraglutide, despite strong data from the initial trial.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IRWD_OUT_5 [2025-04-29 09:14:54 -0400] 919 Bytes | 274 tokens | Cum: 1805 tkns (22.56% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T12:07:23Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Cyclacel Pharmaceuticals (NASDAQ:CYCC...
A2 - 2025-04-25T11:31:00Z - Ironwood Raises 2025 Adj. EBITDA Outlook...
A3 - 2025-04-25T11:04:52Z - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjust...
A4 - 2025-04-25T11:22:36Z - Ironwood Raises 2025 Adj. EBITDA Outlook...
A5 - 2025-04-25T11:29:04Z - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjust...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IRWD_OUT_7 [2025-04-29 09:14:55 -0400] 1181 Bytes | 359 tokens | Cum: 2166 tkns (27.07% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Cyclacel Pharmaceuticals (NASDAQ:CYCC), Aardvark Therapeutics (NASDAQ:AARD)**Date: 2025-04-29Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/45064551/12-health-care-stocks-moving-in-tuesdays-pre-market-sessionGainers LogicMark LGMK shares moved upwards by 67.4% to $0.02 during Tuesday's pre-market session. Hims & Hers Health HIMS shares increased by 39.22% to $39.65. The company's market cap stands at $8.8 billion. LifeMD LFMD stock rose 19.83% to $7.31. The company's market cap stands at $325.9 million. Petros Pharma PTPI stock increased by 15.71% to $0.07. The market value of their outstanding shares is at $1.6 million. Aardvark Therapeutics AARD stock increased by 15.61% to $11.7. The company's market cap stands at $250.1 million. Tevogen Bio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IRWD_OUT_9 [2025-04-29 09:14:56 -0400] 1181 Bytes | 342 tokens | Cum: 2510 tkns (31.37% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): Holdings TVGN shares rose 14.14% to $1.07. The market value of their outstanding shares is at $187.3 million. Losers Iterum Therapeutics ITRM shares decreased by 20.7% to $1.0 during Tuesday's pre-market session. The company's market cap stands at $34.5 million. Relmada Therapeutics RLMD stock fell 14.51% to $0.31. The company's market cap stands at $10.1 million. Cyclacel Pharmaceuticals CYCC stock fell 14.06% to $0.25. The market value of their outstanding shares is at $3.4 million. Universe Pharmaceuticals UPC stock fell 13.45% to $5.15. The company's market cap stands at $78.4 million. Ironwood Pharmaceuticals IRWD stock declined by 11.32% to $0.86. The company's market cap stands at $137.7 million. Senti Biosciences SNTI shares declined by 9.16% to $3.31. The market value of their outstanding shares is at $85.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IRWD_OUT_11 [2025-04-29 09:14:56 -0400] 1058 Bytes | 338 tokens | Cum: 2850 tkns (35.62% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): article was generated by Benzinga's automated content engine and reviewed by an editor.

AARDAardvark Therapeutics Inc$12.0018.6%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum-Price TrendShortMediumLongOverviewCYCCCyclacel Pharmaceuticals Inc$0.2354-17.5%HIMSHims & Hers Health Inc$39.4838.6%IRWDIronwood Pharmaceuticals Inc$0.9700-0.05%ITRMIterum Therapeutics PLC$1.25-0.79%LFMDLifeMD Inc$6.679.34%LGMKLogicMark Inc$0.021062.8%PTPIPetros Pharmaceuticals Inc$0.070722.1%RLMDRelmada Therapeutics Inc$0.3126-12.5%SNTISenti Biosciences Inc$3.42-6.04%TVGNTevogen Bio Holdings Inc$1.0613.1%UPCUniverse Pharmaceuticals Inc$5.17-13.1%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IRWD_OUT_13 [2025-04-29 09:14:58 -0400] 1102 Bytes | 274 tokens | Cum: 3126 tkns (39.07% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-25 8-K Item 2.02 Results of Oper and Fin Cond.

On April 25, 2025, Ironwood Pharmaceuticals, Inc. issued a press release (the Press Release) containing an update on its recent business activities. A copy of the Press Release is furnished as Exhibit 99.1 and is incorpor...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion of our financial condition and results of operations should be read in conjunction with our CONS financial statements and the notes to those financial ...

S4 - 2025-03-27 8-K Item 7.01 Regulation FD Disclosure.

On March 27, 2025, the Company issued a press release in accordance with Nasdaq Listing Rule 5810(b) announcing that the Company had received the Notice. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by r...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IRWD_OUT_15 [2025-04-29 09:14:59 -0400] 1092 Bytes | 257 tokens | Cum: 3385 tkns (42.31% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On April 25, 2025, Ironwood Pharmaceuticals, Inc. issued a press release (the Press Release) containing an update on its recent business activities. A copy of the Press Release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Press Release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IRWD_OUT_17 [2025-04-29 09:15:07 -0400] 9082 Bytes | 2295 tokens | Cum: 5682 tkns (71.03% of 8k)
==========================================================================

This is our set of metrics for Ironwood Pharmaceuticals.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+------------------------+
| Volume: 2,802,462 | Perf Month: -33.53% | Option/Short: Yes / Yes | Sales Y/Y TTM: -20.63% |
+-------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 4.05M | Perf Quarter: -74.46% | Short Float: 7.43% | ROE: -559.14% |
+-------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 0.70 | Index: RUT | Short Ratio: 2.87 | ROI: 0.61% |
+-------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 42.56 | Market Cap: 157.04M | Short Interest: 11.64M | Sales Surprise: -3.44% |
+-------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.13 | Shs Outstand: 160.21M | Beta: 0.38 | EPS Surprise: -76.36% |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA20: -3.76% | Shs Float: 156.66M | Sales Q/Q: -22.98% | P/E: 89.86 |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA50: -28.65% | Inst Own: 101.45% | Sales past 5Y: -3.28% | Earnings: Feb 27 BMO |
+-------------------+-----------------------+-------------------------+------------------------+
| SMA200: -73.07% | Insider Own: 3.18% | Employees: 253 | |
+-------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 37.68% | Insider Trans: -4.81% | Debt/Eq: - | |
+-------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Ironwood Pharmaceuticals officers or majority shareholders (if available).

Inside Trans: IRONWOOD PHARMACEUTICALS INC (IRWD) by DENNER ALEXANDER J (Unknown Title) on 2025-04-02
- Class A Common Stock: 10416 shares at $0 (D) Footnote: Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

No transactions recorded.

Inside Trans: IRONWOOD PHARMACEUTICALS INC (IRWD) by Martini Gregory S. (Chief Financial Officer) on 2025-02-10
- Class A Common Stock: 12052 shares at $1.76 (D) Footnote: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

Inside Trans: IRONWOOD PHARMACEUTICALS INC (IRWD) by John Minardo (Chief Legal Officer) on 2025-02-10
- Class A Common Stock: 122222 shares at $0 (D) Footnote: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- Class A Common Stock: 38938 shares at $1.76 (D) Footnote: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

Inside Trans: IRONWOOD PHARMACEUTICALS INC (IRWD) by Shetzline Michael (SVP, CMO, Head-Res&Drug) on 2025-02-10
- Class A Common Stock: 133333 shares at $0 (D) Footnote: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- Class A Common Stock: 41269 shares at $1.76 (D) Footnote: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

Inside Trans: IRONWOOD PHARMACEUTICALS INC (IRWD) by Silver Ronald (Principal Accounting Officer) on 2025-02-10
- Class A Common Stock: 12048 shares at $1.76 (D) Footnote: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 378418000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3121000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.9705
Average Volume: 4344001.75
30-Day High: 1.47
30-Day Low: 0.6479

[Detailed Financials: Q3 2024]
- Total Assets: $389,519,000.00
- Total Liabilities: $700,853,000.00
- Total Equity: $-311,334,000.00
- Current Assets: $178,604,000.00
- Current Liabilities: $49,383,000.00

[Income Statement: Q3 2024]
- Revenue: $91,592,000.00
- Net Income: $3,646,000.00
- Gross Profit: N/A
- Operating Income: $25,636,000.00
- Earnings Per Share (EPS): 0.02

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-17,287,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $395,620,000.00
- Total Liabilities: $321,727,000.00
- Total Equity: $-321,727,000.00
- Current Assets: $178,180,000.00
- Current Liabilities: $45,510,000.00

[Income Statement: Q2 2024]
- Revenue: $94,396,000.00
- Net Income: $-860,000.00
- Gross Profit: N/A
- Operating Income: $24,977,000.00
- Earnings Per Share (EPS): -0.01

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-15,965,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Ironwood Pharmaceuticals (IRWD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Ironwood Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because IRWD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for IRWD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, IRWD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect IRWD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Ironwood Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Ironwood Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Ironwood Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

IRWD_IN_19 [2025-04-29 09:15:07 -0400] 126 Bytes | 29 tokens | Cum: 5905 tkns (73.81% of 8k)
==========================================================================

====================================
[2025-04-29 09:15:07] # Analysis Completed
Elapsed Time: 15.61 seconds